Epigenomics, BioChain ink agreement
BERLIN—Epigenomics AG and BioChain have signed an agreement for a broad strategic collaboration, part of which expands the license agreement announced earlier in 2013. BioChain will acquire an exclusive license for the development and commercialization of Septin9 in-vitro diagnostic tests for colorectal cancer screening in the Chinese market. Epigenomics will receive upfront and minimum annual payments of undisclosed amounts as well as mid-single-digit royalty payments once Septin9 receives Chinese Food and Drug Administration approval, and BioChain will be funding a clinical trial to validate the assay. BioChain and Epigenomics will also collaborate to validate other methylation biomarkers in oncology. Should they develop any future products, BioChain will have an option to acquire commercialization rights in the Chinese market, while Epigenomics will hold the rights for the rest of the world.